Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community.

Objective In this study, we aimed to evaluate the association between the monoclonal antibody infusion, bamlanivimab, and a reduction in 30-day hospitalization and mortality rates in patients with coronavirus disease 2019 (COVID-19) in a rural community setting with various comorbidities. Methodology A retrospective data analysis was conducted over a 60-day period for patients who visited the Emergency Department of a community hospital. A group of COVID-19-positive patients who received bamlanivimab was compared with another group of COVID-19 patients with similar characteristics, demographics, and disease severity who did not receive the infusion.

Atypical teratoid rhabdoid tumor in the cerebellum of a 7-year-old boy presenting with headache after a fall.

A 7-year-old boy presented to a community emergency department (ED) after sustaining a minor fall. Although he was found to have a normal neurologic examination, additional history revealed the patient had been having mild intermittent headaches and dizziness in the months preceding the fall. The emergency clinicians ordered neuroimaging, which demonstrated a right cerebellar mass, ultimately diagnosed as atypical rhabdoid/teratoid tumor.